Stockreport

Kali and Sanofi sign licence agreement for KT501 autoimmune disease antibody [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF The agreement grants Sanofi worldwide rights to KT501, which is under evaluation in a first-in-human clinical trial for rheumatoid arthritis, focusing on tolerability, [Read more]